SQLite Web: event_store.db

Update row 62628 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-17T02:13:18.114675+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:c3a410d6e06b563c","evidence_event_ids":["evt_5ae842166ea7"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","article_chars":2177,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_78f84d4f261a6f21","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","content_type":"text/plain","enriched_at":"2026-04-17T06:22:27.851674+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","source_event_id":"evt_5ae842166ea7","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"a57248f5ef7e8e02","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-14","2026-04-16","2026-05-18","2025-11-11","2013-02-20","2008-06-25"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"person","name":"Gary A. Lyons","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Common Stock","relevance":"high","symbol":"","type":"security"},{"asset_class":"equity_derivative","name":"Stock option (right to buy)","relevance":"medium","symbol":"","type":"security"}],"event_type":"listing","information_gaps":["The provided text does not clearly state whether the reported transaction is an outright sale after option exercise versus a sale of option shares; it only states \u201csale of shares underlying a stock option.\u201d","The provided text includes price-related fields (e.g., 16.33 and 41.07) but does not explicitly label them as sale price vs. exercise price in a way that can be unambiguously mapped.","No prior known state is included in the signal beyond the generic \u201cdelta\u201d framing, so the exact change vs prior state cannot be determined from the provided text alone."],"key_facts":["SEC filing: Form 4 (CONFORMED SUBMISSION TYPE: 4).","Issuer: Travere Therapeutics, Inc. (TVTX).","Reporting person: Gary A. Lyons (CENTRAL INDEX KEY: 0001123343).","Conformed period of report: 2026-04-14; filed as of date: 2026-04-16.","The transaction described as a sale of shares underlying a stock option granted to the reporting person with an expiration date of 2026-05-18.","The stock option is stated as fully vested and exercisable.","The sale was made pursuant to a written plan adopted on 2025-11-11 meeting Rule 10b5-1(c) requirements.","The filing shows 8,000 shares in the transaction lines (quantity appears as 8000).","The filing includes a signature: /s/ Elizabeth E. Reed, Attorney-in-Fact dated 2026-04-16."],"numeric_claims":[{"label":"shares_quantity","value":"8000"},{"label":"option_expiration_date","value":"2026-05-18"},{"label":"10b5-1_plan_adoption_date","value":"2025-11-11"},{"label":"conformed_period_of_report","value":"2026-04-14"},{"label":"filed_as_of_date","value":"2026-04-16"}],"primary_claim":"Form 4 filed 2026-04-16 by Travere Therapeutics, Inc. reports a sale of 8,000 shares underlying a fully vested stock option (expiring 2026-05-18) by Gary A. Lyons pursuant to a Rule 10b5-1(c) plan adopted 2025-11-11.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Travere Therapeutics, Inc. (TVTX) filed a Form 4 on 2026-04-16 reporting a transaction by reporting person Gary A. Lyons. The filing indicates the sale of shares underlying a fully vested, exercisable stock option expiring May 18, 2026, pursuant to a Rule 10b5-1(c) plan adopted on November 11, 2025.","topics":["SEC Form 4","insider transaction","Rule 10b5-1(c) plan","stock option exercise/sale","common stock"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 4","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel